Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
800 participants
OBSERVATIONAL
2019-07-30
2024-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will help identify the infections leading to death in babies on UK neonatal units, define the clinical characteristics of babies dying from infections, and describe the management of babies dying from infections with a specific focus in their antimicrobial treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in China
NCT05089760
Validation of Biomarkers Performance to Reduce Antibiotics overUse in newBorns With Suspected Clinical Signs of InfectionS
NCT06058819
Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study
NCT01975493
Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis
NCT03453177
Multi-resistant and Spore-forming Bacteria in a Neonatal Intensive Care Unit
NCT06391463
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Through our study we aim to understand and describe better those infections and risk factors that lead to death. The case-control study will enable us to determine if gaps in optimal management, such as the wrong antibiotic or the wrong dose, are associated with poor outcomes. We can then translate such information into practice and develop / improve clinical guidance in order to improve outcomes.
For the purpose of this study, we will request information on the baby's status (alive/died/not known) at 28 days after the positive culture was obtained. If the baby is alive, then this baby becomes eligible as a control. If the baby has died, then further details will be sought including the date of death and whether death was attributed to the infection.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
28 Days
12 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Antibiotic Research UK
UNKNOWN
St George's, University of London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eva Galiza, MD
Role: PRINCIPAL_INVESTIGATOR
St George's, University of London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St George's University of London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019.0048
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.